CA-NETAPP
12.5.2020 20:23:04 CEST | Business Wire | Press release
NetApp (NASDAQ: NTAP), the leader in cloud data services, today announced the appointment of Cesar Cernuda as president of NetApp, reporting to CEO George Kurian, effective in July. He will lead our global go-to-market operations spanning sales, marketing, services, and support. Cernuda joins NetApp from Microsoft, where he was president of Microsoft Latin America and corporate vice president of Microsoft Corporation. He brings with him extensive experience in leading business transformation, building diverse, high-performing teams, and driving a successful cloud business. In his role as president, Cernuda will continue to evolve the NetApp® go-to-market strategy and organization to accelerate growth by transforming how we approach the changing customer landscape and capture new growth opportunities, particularly in cloud.
Today’s technologies and the rapid pace of digital innovation have created new opportunities for organizations to engage with and serve their customers. To capture these opportunities, NetApp’s marketing, sales, and services and support organizations will be combined under Cernuda to create an integrated, global go-to-market organization. Cernuda’s experience in leading global enterprise sales and transforming business will enable him to foster tighter alignment between the teams, helping NetApp to quickly capture new growth opportunities in enterprise storage systems and cloud data services.
“As we look to accelerate our cloud and software strategy, Cesar’s experience in successfully transforming large global organizations will strengthen NetApp’s position as a leader in cloud data services and drive value for our shareholders,” said George Kurian, chief executive officer. “I’m excited to welcome a leader of his caliber. I look forward to him bringing to the team his passion for strong results, his commitment to building diverse, high-performing teams, and his experience in business transformation as we continue to evolve our go-to-market strategy to reflect the changing customer landscape.”
“I believe that NetApp will become a key partner in every organization’s data strategy, and I am looking forward to being a part of it,” said Cernuda. “During the past years, the key hyperscale public cloud vendors have bet on NetApp technology to support them with their customer offerings, and I believe this is one of the best examples of how NetApp has been transforming to become a cloud-first organization. I am thrilled with the opportunity to help and support customers and partners across the globe manage and protect one of their most important assets—their data.”
About Cesar Cernuda
Before joining NetApp, Cernuda served as president of Microsoft Latin America and corporate vice president of Microsoft Corporation, where he was responsible for all of Microsoft’s products, services, and support offerings across Latin America, and for accelerating the company’s transformation for the mobile-first, cloud-first era.
Before that, Cernuda was president of Microsoft Asia Pacific, where he led the company’s commercial and consumer products and service and support offerings. He also served as the worldwide vice president of Microsoft Business Solutions sales and field operations. He oversaw the Microsoft ERP and CRM go-to-market business worldwide. Earlier, he was vice president of Microsoft Business Solutions International, where he was responsible for sales, presales, channel, marketing, product, support, and services.
Cernuda earned a bachelor’s degree in business administration and marketing from ESIC University in Spain and completed a management development program (PDD) from IESE Business School at the University of Navarra in Spain. In 2012, he completed the “Leadership for Senior Executives” program offered by Harvard Business School. Cernuda is an independent board member of GESTAMP, a multinational company that specializes in the design, development, and manufacture of highly engineered metal components for the automotive industry.
About NetApp
NetApp is the leader in cloud data services, empowering global organizations to change their world with data. Together with our partners, we are the only ones who can help you build your unique data fabric. Simplify hybrid multicloud and securely deliver the right data, services, and applications to the right people at the right time. Learn more at www.netapp.com .
NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005824/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom